Fusion Therapy - a new approach to combining treatments

By Dr Thomas Mehrling
Fall 16
Increasingly, oncology agents are being used in combination. However, with complications such as drug resistance and unfavourable side-effect profiles, researchers have been looking for n...

An Update on Hepatitis B Therapies

By Dr John Sullivan-Bolyai
Fall 16
The hepatitis B crisis is a worldwide unmet medical need. Hepatitis B (HBV) is the cause of a silent epidemic that has resulted in a worldwide healthcare crisis. Despite the significant b...

Cell and gene therapies - the emerging fourth pillar of healthcare systems

By Keith Thompson
Fall 16
As the CEO of an organisation that deals exclusively in cell and gene therapies, it is no surprise that I would champion the emergence of these products as the fourth pillar of medicine a...

Ex Vivoverus in Vivo - the challenge of generating meaningful results with traditional cell culture

By Dr James Lim and Dr Fred Aswad
Summer 2016
While the use of human cell lines has become a permanent fixture in drug discovery and development, the lingering issue has been in their inconsistent results.

The Human Micobiome- a new frontier in drug discovery

By Lee Jones Drug
Summer 2016
There is a new phenomenon sweeping the globe (or at least sweeping the imagination of people around the globe). It is the human gut microbiome and the role it may play in the future of hu...

Synthetic lethality and anti cancer drug discovery..

By Jonathan D Moore
Spring 2016
Classically-activated oncogene targets have been a mainstay of cancer drug discovery for the past 15 years, but the druggable targets in this category have been largely mined out.

The role of immunodeficient animal models in advancing immuno-oncology research

By Dr Michael Seiler
Spring 2016
From inbred wild-type to more advanced genetically-engineered strains, mouse models enable researchers to gain important insights into the complex biological underpinnings of human cancer.

The Stem Cell Dilemma: reprogramming in-house versus off-the-shelf purchase of commerciallyproduced iPSC-derived cell types.

by Dr John Comley
Spring 16
The case for using more physiologically-relevant cells for modelling disease pathophysiology, for understanding a drug’s mechanism of action, in toxicology/safety testing and in phenoty...

CAR-T : Looking beyond the hype.

By Christoph Oldenburg, Dr Markus Thunecke and Dr John Herrmann
Winter 2015/16
While CAR-Ts have already demonstrated convincing efficacy in a specific setting, the jury is still out on whether they are a ‘game-changer’ for oncology as a whole and can justify cu...

The use of syngeneic models for the discovery of targets for combination therapy and predictive biomarkers of immunotherapy efficacy.

By Dr Jean- Pierre Wery
Winter 2015/16
Optimal treatment for any disease is one that can cure or prevent spreading with minimal impact on the patient’s quality of life. In the case of cancer, therapeutic agents were initiall...

Valuation in portfolio management.

By Dr Michel Azoulay
Winter 2015/16
Throughout the course of my career, I have been involved in a wide range of portfolio decisions and continue to be involved in them today. Over the years, it has been observed that despit...

RNA based drugs and vaccines will launch a new era of information driven medicine.

By Dr Ingmar Hoerr
Fall 2015
Messenger RNA (mRNA), the naturally occurring molecule honed over thousands of years of evolution to translate accurately and efficiently the information encoded in a cell's DNA into the ...

The California Institute for Regenerative Medicines Human iPSC Initiative.

By Dr Thomas J. Novak
Fall 2015
Large-scale generation of patient-derived induced pluripotent stem cells to accelerate the understanding of disease biology and drug discovery. In 2012, the California Institute for Regen...

The development of cell-based assays for pain drug discovery.

By Dr Paul Karila and Dr Charlotta Blom
Summer 2015
Since the completion of the Human Genome Project and the beginning of the so-called genomics era in the 1990s, a molecular target-based approach has been the method of choice for drug dis...

Anti-infective immunotherapy for treating hospital acquired infections.

By Dr Vu Truong, Dr Nadine Weich, Dr Andreas Loos and Dr Eric Patzer
Summer 2015
The frequency of nosocomial (acquired in healthcare facility) pneumonia has experienced a steady increase in recent years, and treatment of these infections has become more challenging an...

Experimental therapeutics for celiac disease and refractory celiac disease.

By Dr Francisco Leon and Beth Llewellyn
Spring 2015
Celiac disease is a permanent immunological intolerance to gluten proteins in genetically predisposed individuals. In celiac patients, gluten causes a systemic autoimmune disease which st...